Study of UCART19 in Pediatric Patients With Relapsed/Refractory B Acute Lymphoblastic Leukemia
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Blood Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any - 17 |
| Updated: | 11/30/2018 |
| Start Date: | June 3, 2016 |
| End Date: | April 2020 |
A Phase 1, Open Label, Non-comparative Study to Evaluate the Safety and the Ability of UCART19 to Induce Molecular Remission in Paediatric Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukaemia
This study aims at evaluating the safety and feasibility of UCART19 to induce molecular
remission in pediatric patients with relapsed or refractory CD19-positive B-cell acute
lymphoblastic leukemia (B-ALL).
remission in pediatric patients with relapsed or refractory CD19-positive B-cell acute
lymphoblastic leukemia (B-ALL).
Inclusion Criteria:
- Patient with relapsed or refractory CD19-positive B-acute lymphoblastic leukaemia
(B-ALL) who have exhausted alternative treatment options.
- Estimated life expectancy ≥ 12 weeks
- Lansky (age < 16 years at the time of assent/consent) or Karnofsky (age ≥ 16 years at
time of assent/consent) performance status ≥ 50
Exclusion Criteria:
- Burkitt leukemia
- CD19-negative B-cell leukemia
- Active Central Nervous System (CNS) leukemia
- Active acute or chronic Graft-versus-Host Disease (GvHD) requiring systemic use
therapy
We found this trial at
3
sites
Childrens Hospital Los Angeles Children's Hospital Los Angeles is a 501(c)(3) nonprofit hospital for pediatric...
Click here to add this to my saved trials
Children's Hospital of Philadelphia Since its start in 1855 as the nation's first hospital devoted...
Click here to add this to my saved trials
Click here to add this to my saved trials